Johnson & Johnson-Backed Biotech
Cytonics Corporation is an emerging biotech company.
Backed by Johnson & Johnson, this company focuses on molecular diagnostics and therapeutic products for chronic musculoskeletal diseases. Its initial focus is on treating patients suffering from osteoarthritis.
Essentially, Cytonics is targeting these patients with a pair of technologies. The first is a test that assesses a subject’s risk of osteoarthritis. The second is a system that concentrates a special protein in the blood that can be used to treat damaged joints.
This system has treated more than 7,000 patients nationwide, and has been shown to alleviate pain and slow joint damage.
Cytonics is seeking capital to continue advancing these technologies, and to develop its latest discovery: a synthetic version of the blood protein that has the potential to cure osteoarthritis.
Joey has more than 10 years of experience in biotech research & development and investment banking. Specifically, his expertise includes initiating clinical trials, filing and maintaining patent protection, and identifying strategic buyers.
Prior to his role with Cytonics, he was Vice President of Investment Banking with Affinia Capital, where he focused on companies in the biotech and life sciences industries. Before that, he was an investment banking associate with CG Capital Markets.
Earlier in his career, he was a graduate researcher at Johns Hopkins University, where he focused on protein engineering of cell pathways related to blood cancers. He began as a research specialist at the University of Virginia, where he focused on technologies to measure activity related to cancer biology.
Joey has a Bachelor’s degree in Biomedical Engineering from the University of Virginia and a Master’s degree in Bioengineering from Johns Hopkins.
Phil joined Cytonics in December 2020. He's spent nearly three decades forming relationships with big pharma and venture-backed biotech companies.
Prior to joining the company, he was a Program Director at the National Institutes of Health. He was also a research fellow in drug discovery and development at Merck and Avera Pharmaceuticals, and a senior analyst at GQG Partners, a $56 billion global hedge fund.
He holds a Bachelor’s degree in Chemistry from NYU, a Master’s degree in Biochemistry from Florida State, and a Ph.D. in Biochemistry from the University of Florida.
Lewis has nearly 30 years of research experience in pharmaceutical and biotechnology companies. He focuses on the structure and function of proteins, and has a background in the regulatory requirements to obtain FDA new drug approval.
While at Cytonics, he directed research that led to the discovery of the company’s FACT system, as well as research on a biomarker that’s led to deeper understanding of its effect on osteoarthritis.
Prior to joining Cytonics, he was Director of Process Development at Alexion Pharmaceutical, where he directed a group of 15 scientists developing therapeutic antibodies. Before that, he was a principal scientist at Bristol Myers Squibb, a pharmaceutical company, as well as the R. W. Johnson Pharmaceutical Research Institute.
Lewis earned a Bachelor’s degree from Cairo University and a Ph.D. from City University of New York. He also completed a post-doctoral fellowship at Cornell University.
Gaetano has been practicing medicine since 1993. After graduating medical school from the State University of New York, he completed his residency at the University of Miami School of Medicine.
From there, he worked for Fellow Spine Surgery at the University of California San Diego, then became a clinical assistant professor of orthopaedic surgery at Stanford University.
In addition to his role with Cytonics Corporation, he has spent the past eight years as an orthopaedic surgeon with Palm Beach Spine and Sport.
An investment firm focused on incubating and funding early-stage companies.